0 12 Amelioration Amelioration NNP 13 15 of of IN 16 19 rat rat NN 20 28 cerulein cerulein NN 29 41 pancreatitis pancreatitis NN 42 44 by by IN 45 61 guamerin-derived guamerin-derived JJ 62 69 peptide peptide NN 69 70 , , , 71 72 a a DT 73 78 novel novel JJ 79 87 elastase elastase NN 88 97 inhibitor inhibitor NN 97 98 . . . 100 109 Increased increase VBN 110 118 activity activity NN 119 121 of of IN 122 129 various various JJ 130 139 proteases protease NNS 140 142 is be VBZ 143 151 observed observe VBN 152 154 in in IN 155 159 both both CC 160 165 human human JJ 166 169 and and CC 170 182 experimental experimental JJ 183 195 pancreatitis pancreatitis NN 195 196 ; ; : 197 204 however however RB 204 205 , , , 206 209 the the DT 210 221 information information NN 222 224 on on IN 225 228 the the DT 229 236 effects effect NNS 237 239 of of IN 240 248 specific specific JJ 249 257 protease protease NN 258 268 inhibitors inhibitor NNS 269 271 on on IN 272 275 the the DT 276 283 disease disease NN 284 286 is be VBZ 287 294 limited limit VBN 294 295 . . . 296 298 In in IN 299 303 this this DT 304 309 study study NN 310 312 we we PRP 313 317 show show VBP 318 322 that that IN 323 324 a a DT 325 330 novel novel JJ 331 339 elastase elastase NN 340 349 inhibitor inhibitor NN 349 350 , , , 351 367 guamerin-derived guamerin-derived JJ 368 377 synthetic synthetic JJ 378 385 peptide peptide NN 386 387 ( ( ( 387 391 GDSP GDSP NNP 391 392 ) ) ) 392 393 , , , 394 402 improves improve VBZ 403 406 the the DT 407 417 parameters parameter NNS 418 420 of of IN 421 437 cerulein-induced cerulein-induced JJ 438 443 acute acute JJ 444 456 pancreatitis pancreatitis NN 457 459 in in IN 460 463 the the DT 464 467 rat rat NN 467 468 . . . 469 472 The the DT 473 480 effects effect NNS 481 483 of of IN 484 488 GDSP GDSP NNP 489 491 on on IN 492 502 pancreatic pancreatic JJ 503 509 weight weight NN 509 510 , , , 511 516 serum serum NN 517 524 amylase amylase NN 525 528 and and CC 529 535 lipase lipase NN 535 536 , , , 537 548 morphologic morphologic JJ 549 556 changes change NNS 557 559 in in IN 560 563 the the DT 564 572 pancreas pancreas NN 572 573 , , , 574 584 neutrophil neutrophil NN 585 597 infiltration infiltration NN 597 598 , , , 599 602 and and CC 603 610 nuclear nuclear JJ 611 617 factor factor NN 618 620 KB KB NNP 621 622 ( ( ( 622 627 NF-KB NF-KB NNP 627 628 ) ) ) 629 639 activation activation NN 640 644 were be VBD 645 653 measured measure VBN 654 656 in in IN 657 661 rats rat NNS 662 669 infused infuse VBN 670 674 with with IN 675 687 supramaximal supramaximal JJ 688 692 dose dose NN 693 695 of of IN 696 704 cerulein cerulein NN 705 706 ( ( ( 706 707 5 5 CD 708 709 ( ( ( 709 715 g/kg/h g/kg/h NN 715 716 ) ) ) 717 720 for for IN 721 722 6 6 CD 723 724 h h NN 724 725 . . . 726 729 The the DT 730 737 effects effect NNS 738 740 of of IN 741 745 GDSP GDSP NNP 746 750 were be VBD 751 755 also also RB 756 764 measured measure VBN 765 767 on on IN 768 778 superoxide superoxide NN 779 788 formation formation NN 789 791 by by IN 792 801 activated activate VBN 802 807 human human JJ 808 819 neutrophils neutrophil NNS 819 820 . . . 821 824 The the DT 825 832 effects effect NNS 833 835 of of IN 836 840 GDSP GDSP NNP 841 845 were be VBD 846 854 compared compare VBN 855 859 with with IN 860 865 those those DT 866 868 of of IN 869 876 another another DT 877 885 elastase elastase NN 886 895 inhibitor inhibitor NN 895 896 , , , 897 908 elastatinal elastatinal JJ 908 909 . . . 910 914 GDSP GDSP NNP 915 928 significantly significantly RB 929 938 inhibited inhibit VBD 939 944 edema edema NN 945 954 formation formation NN 954 955 , , , 956 966 neutrophil neutrophil NN 967 979 infiltration infiltration NN 979 980 , , , 981 987 acinar acinar JJ 988 992 cell cell NN 993 999 damage damage NN 999 1000 , , , 1001 1004 and and CC 1005 1011 plasma plasma NN 1012 1018 lipase lipase NN 1019 1022 and and CC 1023 1030 amylase amylase NN 1031 1040 increases increase NNS 1041 1047 caused cause VBN 1048 1050 by by IN 1051 1059 cerulein cerulein NN 1059 1060 . . . 1061 1065 GDSP GDSP NNP 1066 1070 also also RB 1071 1081 completely completely RB 1082 1091 inhibited inhibit VBD 1092 1102 superoxide superoxide NN 1103 1112 formation formation NN 1113 1115 in in IN 1116 1119 the the DT 1120 1125 human human JJ 1126 1137 neutrophils neutrophil NNS 1138 1148 stimulated stimulate VBN 1149 1151 by by IN 1152 1194 N-formyl-methionine-leucine-phenyl-alanine N-formyl-methionine-leucine-phenyl-alanine NNP 1195 1196 ( ( ( 1196 1200 fMLP fMLP NNP 1200 1201 ) ) ) 1202 1204 or or CC 1205 1241 12-O-tetradecanoylphorbol-13-acetate 12-O-tetradecanoylphorbol-13-acetate NNP 1242 1243 ( ( ( 1243 1246 TPA TPA NNP 1246 1247 ) ) ) 1247 1248 . . . 1249 1260 Elastatinal Elastatinal NNP 1261 1264 had have VBD 1265 1269 some some DT 1270 1272 of of IN 1273 1276 the the DT 1277 1281 same same JJ 1282 1289 effects effect NNS 1290 1292 as as IN 1293 1297 GDSP GDSP NNP 1298 1301 but but CC 1302 1305 was be VBD 1306 1310 less less RBR 1311 1317 potent potent JJ 1318 1321 and and CC 1322 1331 effective effective JJ 1331 1332 . . . 1333 1338 These these DT 1339 1346 results result NNS 1347 1358 demonstrate demonstrate VBP 1359 1360 a a DT 1361 1371 beneficial beneficial JJ 1372 1378 effect effect NN 1379 1381 of of IN 1382 1386 GDSP GDSP NNP 1386 1387 , , , 1388 1389 a a DT 1390 1395 novel novel JJ 1396 1404 specific specific JJ 1405 1413 elastase elastase NN 1414 1423 inhibitor inhibitor NN 1423 1424 , , , 1425 1427 on on IN 1428 1431 the the DT 1432 1443 development development NN 1444 1446 of of IN 1447 1450 rat rat NN 1451 1459 cerulein cerulein NN 1460 1472 pancreatitis pancreatitis NN 1472 1473 . . .